Clinical trial
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With…
NCT00189553 · ARCAGY/ GINECO GROUP, Other · Completed
Key facts
| NCT number | NCT00189553 |
|---|---|
| Title | Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse |
| Official title | A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) |
| Acronym | CALYPSO |
| Lead sponsor | ARCAGY/ GINECO GROUP, Other |
| Collaborators | Schering-Plough Industry Arbeitsgemeinschaft Gynaekologische Onkologie Austria AGO Study Group Australia New Zealand Gynaecological Oncology Group European Organisation for Research and Treatment of… |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | Pegylated liposomal doxorubicin, Carboplatin, Paclitaxel |
| Enrollment | 976 |
| Start date | Apr 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jun 1, 2012 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 10, 2014 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: